Kevin O'Connor, Ph.D., a partner in the firm's Intellectual Property practice group, was quoted in the article "Debate Over COVID-19 Product IP Flares Up Again," which was recently published by Chemical & Engineering News. The article explores the WTO debate concerning IP waivers for COVID-19 products and treatments for low- and middle-income countries.

Some say that the waivers could have a detrimental effect on future innovation. "Companies might think twice about jumping in the next time such a health crisis arises, if that investment is going to be then turned around and essentially given away,” said Kevin.

Click here to read the article.